Skip to content
Dosage GuideResearch Reference

CGRP Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for CGRP. All information is for educational purposes only.

Quick Answer

CGRP is typically not administered exogenously. Current CGRP-related therapies focus on blocking CGRP or its receptor via monoclonal antibodies or small molecule antagonists. Dosage for these therapies vary.

→ CGRP Benefits→ CGRP Side Effects→ Full CGRP Profile
Table of Contents

Standard Dosage Range

Research dosing range: N/A (CGRP itself not typically dosed exogenously)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Migraine Prevention (Anti-CGRP mAb: Erenumab)

70 mg or 140 mgMonthly (Subcutaneous Injection)
Duration

Ongoing (maintenance therapy)

Administered monthly via subcutaneous injection. Dosage can be adjusted based on efficacy and tolerability.

Migraine Prevention (Anti-CGRP mAb: Fremanezumab)

225 mgMonthly (Subcutaneous Injection) or 675mg Quarterly
Duration

Ongoing (maintenance therapy)

Administered monthly or quarterly via subcutaneous injection. Quarterly dose may be more convenient for some patients.

Migraine Prevention (Anti-CGRP mAb: Galcanezumab)

120 mg (loading dose 240mg)Monthly (Subcutaneous Injection)
Duration

Ongoing (maintenance therapy)

Administered monthly via subcutaneous injection. A loading dose is given initially.

Migraine Prevention (Anti-CGRP mAb: Eptinezumab)

100 mg or 300 mgQuarterly (Intravenous Infusion)
Duration

Ongoing (maintenance therapy)

Administered quarterly via intravenous infusion.

Acute Migraine Treatment (CGRP Receptor Antagonist: Rimegepant)

75 mgAs needed, up to once daily
Duration

Single dose for acute attack

Oral tablet taken at the onset of migraine symptoms. Do not exceed one dose in 24 hours.

Acute Migraine Treatment (CGRP Receptor Antagonist: Ubrogepant)

50 mg or 100 mgAs needed, up to once daily
Duration

Single dose for acute attack

Oral tablet taken at the onset of migraine symptoms. A second dose may be taken after 2 hours if needed.

Timing & Frequency

Anti-CGRP monoclonal antibodies are generally administered monthly or quarterly as maintenance therapy. CGRP receptor antagonists are taken as needed for acute migraine attacks.

Cycle Guidance

Anti-CGRP monoclonal antibody treatments are typically continued long-term for migraine prevention. CGRP receptor antagonists are used only as needed for acute attacks.

Reconstitution Reference

Quick reference for reconstituting CGRP. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeN/A (Monoclonal antibodies and gepants are pre-formulated)
BAC Water VolumeN/A
Concentration & DrawN/A
StorageStore according to manufacturer instructions.
StabilityFollow manufacturer guidelines for storage and stability.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What are common dosages for anti-CGRP migraine medications?
Dosages vary depending on the specific medication. Erenumab is typically 70 mg or 140 mg monthly, Fremanezumab is 225 mg monthly or 675mg quarterly, and Galcanezumab is 120 mg monthly. Rimegepant is 75 mg as needed for acute migraine.
How are anti-CGRP monoclonal antibodies administered?
They are administered via subcutaneous injection (Erenumab, Fremanezumab, Galcanezumab) or intravenous infusion (Eptinezumab).
Are there any concerns about long-term use of anti-CGRP medications?
Long-term safety data is still being collected, but current studies suggest that anti-CGRP medications are generally well-tolerated. Monitor for any adverse effects and consult with a healthcare professional.

Last updated: 2026-02-19